# Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism

> **NCT07197450** · EARLY_PHASE1 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 6 (estimated)

## Conditions studied

- Hypoparathyroidism

## Interventions

- **DRUG:** intravenous administration of PTH1-84 mRNA

## Key facts

- **NCT ID:** NCT07197450
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-20
- **Primary completion:** 2026-04-15
- **Final completion:** 2026-04-30
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07197450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07197450, "Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07197450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*